On April 9, 2026, Quince Therapeutics, Inc. approved a 1-for-10 reverse stock split effective April 10, 2026, resulting in approximately 16,300,795 outstanding shares. This split will not affect ownership percentages except for fractional shares, which will be paid in cash.